---
schema_version: "secwatch.filing_event.v1"
accession: "0000950123-22-010618"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T20:38:29.406144+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance

## Summary
- Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.
- EPS $2.15, +6% reported, +13% comparable; operating margin 29.1%, +100 bps comparable.
- Record global premium instrument placements, +10% YoY; installed base +14%.
- FY2022 guidance: revenue growth 3.5-4.5% reported, 6.5-7.5% organic; EPS $7.74-$7.98.
- Foreign currency headwinds: ~4% revenue impact, ~$0.25 EPS impact for FY2022.

## SEC filing metadata
- accession: 0000950123-22-010618
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/0000950123-22-010618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/idxx-8k_20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950123-22-010618
- JSON: https://secwatch.observer/filing/0000950123-22-010618.json
- Plain text: https://secwatch.observer/filing/0000950123-22-010618.txt

## Key facts
- Earnings Releases
  IDEXX LABORATORIES INC /DE reported the quarter ended September 30, 2022 results: revenue $842 million, EPS $2.15. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $842 million
  - EPS: $2.15
  - Guidance: reaffirmed
  - Result: reported results
  source text: The Company reports revenues of $842 million for the third quarter of 2022, a 4% increase as reported and 8% organically, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 5% reported and 9% organic, building on strong prior year performance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/0000950123-22-010618-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.